Hrt Financial LP Protagonist Therapeutics, Inc Transaction History

Hrt Financial LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$14.05 - $23.44 $1.03 Million - $1.71 Million	73,126 New	73,126 $1.68 Million
Q4 2022 Feb 10, 2023	SELL	$7.36 - $11.17 $654,878 - $993,884	-88,978 Reduced 41.56%	125,119 $1.37 Million
Q3 2022 Nov 14, 2022	BUY	$7.86 - $11.71 $1.68 Million - $2.51 Million	214,097 New	214,097 $1.8 Million
Q1 2021 May 17, 2021	SELL	$19.02 - $31.15 $343,520 - $562,600	-18,061 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$18.49 - $25.13 $333,947 - $453,872	18,061 New	18,061 $364,000

248

56.7M

76.3K

114K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $1.93B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.